CRISPR Therapeutics AG $CRSP Stock: Pictet Asset Management Holding SA Trims Position

Pictet Asset Management Holding SA decreased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 129,472 shares of the company’s stock after selling 12,741 shares during the period. Pictet Asset Management Holding SA owned 0.13% of CRISPR Therapeutics worth $7,241,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Privium Fund Management B.V. lifted its position in CRISPR Therapeutics by 8.9% in the third quarter. Privium Fund Management B.V. now owns 48,974 shares of the company’s stock valued at $2,709,000 after acquiring an additional 4,000 shares during the last quarter. Pekin Hardy Strauss Inc. purchased a new position in shares of CRISPR Therapeutics during the third quarter worth about $1,481,000. Kestra Advisory Services LLC grew its holdings in shares of CRISPR Therapeutics by 16.1% during the third quarter. Kestra Advisory Services LLC now owns 20,068 shares of the company’s stock worth $1,110,000 after purchasing an additional 2,776 shares during the last quarter. Quadcap Wealth Management LLC grew its holdings in shares of CRISPR Therapeutics by 20.9% during the third quarter. Quadcap Wealth Management LLC now owns 5,739 shares of the company’s stock worth $317,000 after purchasing an additional 992 shares during the last quarter. Finally, Compass Financial Management LLC acquired a new stake in shares of CRISPR Therapeutics during the third quarter worth about $25,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Buying and Selling at CRISPR Therapeutics

In related news, General Counsel James Kasinger sold 1,040 shares of the business’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $49.26, for a total value of $51,230.40. Following the transaction, the general counsel owned 95,857 shares in the company, valued at $4,721,915.82. The trade was a 1.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Samarth Kulkarni sold 47,837 shares of the company’s stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $49.78, for a total value of $2,381,325.86. Following the sale, the chief executive officer directly owned 311,899 shares of the company’s stock, valued at approximately $15,526,332.22. This represents a 13.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 93,558 shares of company stock worth $4,881,663 over the last three months. 5.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently commented on the company. UBS Group started coverage on CRISPR Therapeutics in a research report on Thursday, October 15th. They set a “neutral” rating and a $52.00 target price on the stock. Citizens Jmp reissued a “market outperform” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a research report on Monday, August 31st. Wells Fargo & Company dropped their price target on CRISPR Therapeutics from $75.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 4th. Needham & Company LLC restated a “buy” rating and set a $82.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, November 3rd. Finally, Citigroup lifted their price target on CRISPR Therapeutics from $88.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $72.93.

Read Our Latest Analysis on CRISPR Therapeutics

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $42.24 on Monday. The stock has a market cap of $4.10 billion, a P/E ratio of -8.91 and a beta of 1.92. The firm has a fifty day moving average price of $52.09 and a 200 day moving average price of $52.54. The company has a debt-to-equity ratio of 0.36, a current ratio of 16.21 and a quick ratio of 16.21. CRISPR Therapeutics AG has a 1-year low of $41.75 and a 1-year high of $63.45.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.09). The business had revenue of $12.67 million for the quarter, compared to analysts’ expectations of $14.75 million. CRISPR Therapeutics had a negative return on equity of 25.59% and a negative net margin of 1,812.07%. CRISPR Therapeutics’s quarterly revenue was up 1311.1% on a year-over-year basis. Sell-side analysts predict that CRISPR Therapeutics AG will post -4.54 EPS for the current year.

CRISPR Therapeutics Profile

(Free Report)

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.

Read More

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.